Urate‐Lowering Therapy for Gout: Focus on Febuxostat

@article{Love2010UrateLoweringTF,
  title={Urate‐Lowering Therapy for Gout: Focus on Febuxostat},
  author={Bryan L. Love and Robert Barrons and Angie Veverka and K Snider},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2010},
  volume={30}
}
Gout is a common, painful, and often debilitating rheumatologic disorder that remains one of the few arthritic conditions that can be diagnosed with certainty and cured with appropriate therapy. Allopurinol is the most frequently prescribed agent for gout in the United States. Unfortunately, most patients treated with allopurinol do not achieve target serum uric acid (sUA) levels, possibly due to a perceived intolerability to allopurinol in doses above 300 mg and the need for reduced doses in… Expand
Febuxostat for the treatment of hyperuricemia in patients with gout
TLDR
Febuxostat may be a safe and effective alternative for treating gout patients where allopurinol 300 mg/day is neither safe nor effective. Expand
Efficacy and safety of febuxostat in patients with hyperuricemia and gout
TLDR
Febuxostat's overall efficacy and safety profile is comparable and, in certain subsets such as gout patients with mild and moderate renal insufficiency, is superior to allopurinol. Expand
Febuxostat for the Treatment of Chronic Tophaceous Gout in a Patient on Continuous Ambulatory Peritoneal Dialysis
TLDR
Low-dose febuxostat is a promising alternative to allopurinol for the treatment of gouty arthritis or tophi in peritoneal dialysis patients and considered to be an alternative treatment for hyperuricemic patients with chronic kidney disease. Expand
Pharmacokinetics considerations for gout treatments
TLDR
Canakinumab appears to be a good alternative for patients with contraindications to colchicine, NSAIDs and corticosteroids, and co-prescription with strong CYP3A4 or P-glycoprotein inhibitors can greatly modify its pharmacokinetics is to be avoided. Expand
An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
TLDR
This large multicenter study of allopurinol dose-titration strategy was well tolerated, without new safety signals emerging over 6 months, but despite encouragement to treat to target, significant proportions of patients did not achieve target sUA. Expand
Gout: objective, indications and adherence to uratelowering therapy
TLDR
The lowering therapy is started with a low dose and subsequent titration in all patients with high UA serum levels in the presence of renal pathology, and in such comorbid diseases as hypertension, heart failure, coronary artery disease. Expand
Febuxostat as a Novel Option to Optimize Thiopurines’ Metabolism in Patients With Inadequate Metabolite Levels
TLDR
It has been shown that low dose of febuxostat was able to prevent hypermethylation and to potentiate 6-TGN levels in an AZA-treated patient, and could be useful in optimizing thiopurines’ metabolism. Expand
Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study
TLDR
Long-term persistence of XOIs was suboptimal, and allopurinol had worse persistence rates than febuxostat among patients with gout, suggesting that febUXostat is a better option for long-term ULT in light of medication adherence in a real-world setting. Expand
Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.
TLDR
There is currently an unmet need for additional treatment options for the management of gouty arthritis in patients with CKD. Expand
Hyperuricaemia: more than just a cause of gout?
TLDR
This narrative review considers the significant associations of SUA with kidney function, several CV risk factors and vascular diseases, supporting the concept of assessing hyperuricaemia for reasons other than just gout. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 67 REFERENCES
Emerging therapies in the long‐term management of hyperuricaemia and gout
TLDR
Febuxostat, a new xanthine oxidase inhibitor, is an effective hypouricaemic agent although further data are required for patients with renal impairment and other significant medical conditions. Expand
Management of Acute and Chronic Gouty Arthritis
TLDR
The use of recombinant urate oxidase in patients with chronic gout is limited by the need for parenteral administration, the potential antigenicity and production of anti-urate oxidase antibodies, and declining efficacy. Expand
Therapeutic advances in gout
TLDR
Proper gout management requires changes to the physician's attitude towards the disease; essentially: an unequivocal diagnosis based in urate crystal identification, a clearly settled aim of the treatment: crystal elimination from the joints and elsewhere, and proper use of the available therapeutic alternatives. Expand
Management of acute and chronic gouty arthritis: present state-of-the-art.
TLDR
The use of recombinant urate oxidase in patients with chronic gout is limited by the need for parenteral administration, the potential antigenicity and production of anti-urate oxidase antibodies, and declining efficacy. Expand
Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout
TLDR
Durable maintenance of goal range SUA level with either dose of febuxostat or in smaller numbers of subjects with allopurinol resulted in near elimination of gout flares and improved tophus status over time. Expand
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
TLDR
At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function. Expand
Azathioprine and Allopurinol: The Price of an Avoidable Drug Interaction
TLDR
Undetected drug interactions can be life-threatening to patients as well as costly to the healthcare system and drug interactions also can have a profound negative effect on the patients' quality of life. Expand
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
TLDR
Treatment with febuxostat resulted in a significant reduction of sUA levels at all dosages and was safe and well tolerated. Expand
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
TLDR
Long-term treatment with febuxostat resulted in durable maintenance of serum urate levels < 6.0 mg/dl for most subjects, and there was nearly complete abolition of gout flares in patients completing the study. Expand
Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial
TLDR
Oral prednisolone and naproxen are equally effective in the initial treatment of gout arthritis over 4 days, suggesting equivalence. Expand
...
1
2
3
4
5
...